Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards ...

Licensed for use in the UK in March, Alyftrek will now be immediately funded by the NHS in England. This rapid timeline demonstrates NICE's commitment to getting breakthrough treatments to patients ...

We have recommended the first under-the-tongue tablet immunotherapy shown to build long-term tolerance to allergens, which could help up to 27,000 people in England with moderate to severe birch tree ...

Around 5,700 people with early breast cancer are set to benefit from expanded access to a treatment combination designed to help prevent their cancer from returning, following our recommendation, ...

This information explains the advice about familial breast cancer (breast cancer in the family) that is set out in NICE guideline CG164. This is an update of advice on familial breast cancer that NICE ...

Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies Technology appraisal guidance TA559 Published: 23 ...

May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guidance on treating severe asthma and our ...

COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community NICE guideline NG163 Published: 03 April 2020 Last updated: 13 October 2020 ...

We welcome the publication of the government's Life Sciences Sector Plan, which sets out how NICE will ensure patients get faster, fairer access to transformative new medicines and life-changing ...

Around the world, publicly-funded healthcare systems face a common challenge: ensuring limited resources are allocated to treatments offering the best value for patients and taxpayers. Without robust ...

Suggested remit: To appraise the clinical and cost effectiveness of belantamab mafodotin within its marketing authorisation for treating relapsed or refractory multiple myeloma after 4 or more ...

This guideline covers the diagnosis and management of gout. It includes recommendations on diagnosing gout, managing flares, long-term management of gout and referral to specialist services ...